|
KMID : 1011320130060020079
|
|
Journal of Pharmacoepidemiology and Risk Management
2013 Volume.6 No. 2 p.79 ~ p.86
|
|
|
The Current Status and Preventive Activities of Counterfeit Medicines in the United States
|
|
Kim Hyun-Jung
Jung Sun-Young
Shin Ju-Young
Jung Soo-Youn
Park Byung-Joo
|
|
|
Abstract
|
|
|
|
Counterfeit medicine is a global problem with significant consequences for public health and patient safety, including treatment failure and deaths. The World Health Organization estimates that 6 to 10% of the global medicine market is counterfeit. As the world’s largest market for pharmaceutical sales, counterfeit manufacturers and sellers have targeted the United States as its most profitable market. Unfortunately, there is little information about the current status of the counterfeit medicine. Because the counterfeit activity is very difficult to identify, trace, and combate, the US government and the private sector are trying to work in various fields of activity. To combat counterfeit drugs, the Food and Drug Administration (FDA) created a Counterfeit Drug Task Force to informing counterfeit drug issue to the public, particularly consumers, pharmacists, other health care professionals, wholesalers, and others involved in the US drug distribution system, FDA also educates these parties on ways to identify and report suspected counterfeit medical products to FDA through MedWatch system. And pharmaceutical companies, health professional associations, consumer groups, and other stakeholders, such as the National Association Boards of Pharmacy (NABP) and the Center for Safe Internet Pharmacies (CSIP) are collaborating with FDA. This review aims to introduce the current status and preventive activities of counterfeit medicines in the US and to discuss the possible ways to combate the counterfeit drugs.
|
|
|
KEYWORD
|
|
|
Counterfeit medicines, Preventive activities, Pharmacovigilance
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|